Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Dr Ueda Calls For Increase in CRC and Enhanced Functions of IRB
July 8, 2002
- Otsuka: Consolidated Sales Up 2% to \489.9 Bil.
July 8, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
July 8, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
July 8, 2002
- Ain Pharmaciez: Sales Up 26.1% to \24.7 Bil.
July 8, 2002
- Korosho to Convert OPSR into Independent Administrative Agency in April 2004
July 8, 2002
- Tsuruha Acquires Potato Company of Yamagata
July 8, 2002
- Korosho Quickly Reviews NDA for Useful Drugs
July 8, 2002
- Discussions on Role of OTC Drugs Begin: Korosho
July 8, 2002
- ADRs Likely Caused by Glivec Reported: Korosho
July 8, 2002
- Pharmacists Ranked 5th in FY2002 Honesty/Ethics in Profession Poll
July 8, 2002
- Revised Bill of Health Insurance Law Approved by Lower House
July 8, 2002
- Iwaki Launches Mechanical Ventilators
July 8, 2002
- 75% of the Elderly Enjoy Healthy Life: White Paper
July 1, 2002
- Basic Policy for FY2003 Budget Formation Recommended by Council
July 1, 2002
- Expert Panel Presents Interim Report on IP
July 1, 2002
- REGULATORY NEWS IN BRIEF
July 1, 2002
- Good Initial Market Reactions to Olmesartan: Mr Shoda of Sankyo
July 1, 2002
- Number of ADRs Totals 26,545 in FY2001
July 1, 2002
- Wholesalers' Cooperation Is Essential in Immediate PMS: Teijin
July 1, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…